Milestone Scientific and the Ordway Research Institute have entered into a partnership to develop drug formulations that will be suitable for targeted delivery using Milestone’s patented CompuFlo injection technology.

Under the agreement, Ordway will develop nanoparticulate and other drug reformulations for indications including arthritis and cancer.

Milestone will provide prototype CompuFlo instruments to Ordway to facilitate the development of the drug reformulations.